Summary for Defibrotide


Breastfeeding
  • Trade Name: Defitelio (Jazz)
  • Indications: Hepatic veno-occlusive disease in patients with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
  • Class: Oligonucleotide
  • Half-life: <2 hours
  • FDA Approval Date: 03/30/2016
  • Clinically important, potentially hazardous interactions with:
    Alteplase, Heparin
  • Pregnancy: No data available

Contra-indicated for concomitant administration with systemic anticoagulant or fibrinolytic therapy.

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top